Literature DB >> 21191020

Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin.

Amy J Andrew1, Eri Miyagi, Klaus Strebel.   

Abstract

BST-2/CD317/tetherin is a host factor that inhibits the release of HIV-1 and other unrelated viruses. A current model proposes that BST-2 physically tethers virions to the surface of virus-producing cells. The HIV-1-encoded Vpu protein effectively antagonizes the activity of BST-2. How Vpu accomplishes this task remains unclear; however, it is known that Vpu has the ability to down-modulate BST-2 from the cell surface. Here we analyzed the effects of Vpu on BST-2 by performing a series of kinetic studies with HeLa, 293T, and CEMx174 cells. Our results indicate that the surface downregulation of BST-2 is not due to an accelerated internalization or reduced recycling of internalized BST-2 but instead is caused by interference with the resupply of newly synthesized BST-2 from within the cell. While our data confirm previous reports that the high-level expression of Vpu can cause the endoplasmic reticulum (ER)-associated degradation of BST-2, we found no evidence that Vpu targets endogenous BST-2 in the ER in the course of a viral infection. Instead, we found that Vpu acts in a post-ER compartment and increases the turnover of newly synthesized mature BST-2. Our observation that Vpu does not affect the recycling of BST-2 suggests that Vpu does not act directly at the cell surface but may interfere with the trafficking of newly synthesized BST-2 to the cell surface, resulting in the accelerated targeting of BST-2 to the lysosomal compartment for degradation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191020      PMCID: PMC3067951          DOI: 10.1128/JVI.02080-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.

Authors:  Stuart J D Neil; Virginie Sandrin; Wesley I Sundquist; Paul D Bieniasz
Journal:  Cell Host Microbe       Date:  2007-09-13       Impact factor: 21.023

2.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  A novel membrane antigen selectively expressed on terminally differentiated human B cells.

Authors:  T Goto; S J Kennel; M Abe; M Takishita; M Kosaka; A Solomon; S Saito
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

5.  Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4.

Authors:  R L Willey; F Maldarelli; M A Martin; K Strebel
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.

Authors:  R L Willey; D H Smith; L A Lasky; T S Theodore; P L Earl; B Moss; D J Capon; M A Martin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

7.  Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology.

Authors:  Sabine Kupzig; Viktor Korolchuk; Ruth Rollason; Anna Sugden; Andrew Wilde; George Banting
Journal:  Traffic       Date:  2003-10       Impact factor: 6.215

8.  Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.

Authors:  Kristine M Rose; Mariana Marin; Susan L Kozak; David Kabat
Journal:  J Biol Chem       Date:  2004-08-05       Impact factor: 5.157

9.  Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum.

Authors:  Julie Binette; Mathieu Dubé; Johanne Mercier; Dalia Halawani; Martin Latterich; Eric A Cohen
Journal:  Retrovirology       Date:  2007-10-15       Impact factor: 4.602

10.  Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER.

Authors:  J Lippincott-Schwartz; L C Yuan; J S Bonifacino; R D Klausner
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

View more
  35 in total

1.  Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo.

Authors:  Victor H Leyva-Grado; Rong Hai; Fiona Fernandes; Alan Belicha-Villanueva; Carol Carter; Mark A Yondola
Journal:  J Mol Biol       Date:  2013-12-29       Impact factor: 5.469

Review 2.  HIV-1 Vpu - an ion channel in search of a job.

Authors:  Klaus Strebel
Journal:  Biochim Biophys Acta       Date:  2013-07-03

3.  Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.

Authors:  David Lau; Wilson Kwan; John Guatelli
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

4.  HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.

Authors:  Mathieu Dubé; Catherine Paquay; Bibhuti Bhusan Roy; Mariana G Bego; Johanne Mercier; Eric A Cohen
Journal:  Traffic       Date:  2011-10-03       Impact factor: 6.215

5.  Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence.

Authors:  Andrey Tokarev; John Guatelli
Journal:  Cell Logist       Date:  2011-05

6.  Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase.

Authors:  Kerstin Gnirß; Pawel Zmora; Paulina Blazejewska; Michael Winkler; Anika Lins; Inga Nehlmeier; Sabine Gärtner; Anna-Sophie Moldenhauer; Heike Hofmann-Winkler; Thorsten Wolff; Michael Schindler; Stefan Pöhlmann
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

7.  Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells.

Authors:  Eri Miyagi; Amy Andrew; Sandra Kao; Takeshi Yoshida; Klaus Strebel
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

8.  The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release.

Authors:  Jason Hammonds; Lingmei Ding; Hin Chu; Ken Geller; Andrew Robbins; Jaang-Jiun Wang; Hong Yi; Paul Spearman
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

9.  An N-Glycosylated Form of SERINC5 Is Specifically Incorporated into HIV-1 Virions.

Authors:  Shilpi Sharma; Mary K Lewinski; John Guatelli
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

10.  Stimulation of NF-κB activity by the HIV restriction factor BST2.

Authors:  Andrey Tokarev; Marissa Suarez; Wilson Kwan; Kathleen Fitzpatrick; Rajendra Singh; John Guatelli
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.